SPECIALTY QUANTITY LIMIT PROGRAM

Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors

I. PROGRAM DESCRIPTION

The recommended dosing parameters for all FDA-approved indications that fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Repatha 140 mg syringe or SureClick autoinjector	2 per 28 days	Established cardiovascular disease or primary hyperlipidemia: 140 mg every 2 weeks or 420 mg once monthly
Repatha 420 mg Pushtronex system	1 per 28 days	Homozygous familial hypercholesterolemia: 420 mg once monthly
Praluent 75 mg pen	2 per 28 days	Initial dose: 75 mg every two weeks. If the LDL-C response is inadequate, dosage may be adjusted to the maximum 150 mg every 2
Praluent 150 mg syringe/pen	2 per 28 days	weeks
		Alternative starting dose for less frequent dosing: 300 mg every 4 weeks. If LDL-C response is inadequate, dosage may be adjusted to 150 mg every 2 weeks

III. REFERENCES

- 1. Repatha [package insert]. Thousand Oaks, CA: Amgen, Inc.; December 2017.
- 2. Praluent [package insert]. Bridgewater, NJ: Sanofi-aventis U.S., LLC; September 2017.

Specialty Quantity Limit Repatha-Praluent 1777-H P2019

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

